BP nanosheets |
25–200 µg/mL |
4T1, HeLa, L929, A549 |
Minimal cytotoxicity |
[67] |
BP nanoparticles with dextran (DEX) and branched poly(ethyleneimine) (PEI), and folic acid (FA) |
3.125–100 µg/mL |
4T1, 3T3 |
Minimal cytotoxicity |
[68] |
BP nanosheets with polydopamine (PDA), and zinc oxide (ZnO) nanowires on titanium (Ti) substrates |
20 mg/mL |
MC3T3-E1, L929 |
Minimal cytotoxicity |
[58] |
BP nanosheets with ε-poly-l-lysine (ε-PL) |
0.8–50 µg/mL |
293T, HaCaTs |
Minimal cytotoxicity |
[69] |
BP nanosheets |
12.5–200 µg/mL |
HeLa, HepG-2, MCF-7, L02 |
Minimal cytotoxicity |
[53] |
BP quantum dots in hydrogel (NH) |
50–500 µg/mL |
HUVECs, HaCaTs |
Minimal cytotoxicity |
[65] |
BP nanosheets with silk fibroin (SF) |
50–500 µg/mL |
HSF |
Minimal cytotoxicity |
[70] |
BP sheets |
3.125–400 µg/mL |
A549 |
Intermediate cytotoxicity |
[62] |
BP nanodots |
0.05–3.0 mg/mL |
HeLa, COS-7, CHO-K1 |
Minimal cytotoxicity |
[25] |
BP nanoflakes |
312.5–5000 µg/mL |
HaCaTs, HFF |
Minimal–Intermediate cytotoxicity |
[12] |
Layered BP |
6.25–200 µg/mL |
NIH 3T3, HCoEpiC, 293T |
Minimal–High cytotoxicity |
[63] |
BP nanosheets |
0.3–125 µg/mL |
NIH3T3, nHDF, HT1080 |
Minimal–High cytotoxicity |
[60] |